Meniere Disease - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Meniere Disease (Ear Nose Throat Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Meniere Disease (Ear Nose Throat Disorders) pipeline guide also reviews of key players involved in therapeutic development for Meniere Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 1, 1, 2 and 1 respectively.
Meniere Disease (Ear Nose Throat Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Key Topics Covered:
- Meniere Disease - Overview
- Meniere Disease - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Products under Development by Companies
- Meniere Disease - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Meniere Disease - Companies Involved in Therapeutics Development
- Orbis Biosciences Inc
- Otonomy Inc
- Quark Pharmaceuticals Inc
- Sound Pharmaceuticals Inc
- Synphora AB
For more information about this report visit https://www.researchandmarkets.com/research/kp2rft/meniere_disease